At a glance
ClinicalIndex Comparison Record- ✓Low back pain persisting for more than 6 months
- ✓Age older than 25 years
- ✓MRI findings consistent with lumbar degenerative or osteoarthritic changes
- ✕Spinal stenosis accompanied by neurological deficits
- ✕Spinal prolapse accompanied by neurological deficits
- ✕Rheumatoid arthritis or psoriatic arthritis
- ✕History of old lumbar fractures
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings
In Brief
A Phase 4 clinical trial evaluating Glucosamine sulphate and Placebo for Low Back Pain. Completed, enrolled 250 participants across 1 site.
Detailed Summary
Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability. Some indications exist for symptomatic and possible cartilage-structurmodifying effect on knee- and hip-osteoarthritis with glucosamine sulphate (GS). The OA process in the lumbar spine is most likely to OA processes in knees and hips, hence GS could have comparable symptomatic and structural effect on lumbar OA. Study hypothesis: No difference in treatment effect exists between oral intake of GS- or placebo-capsules for patients' with chronic low back pain measured with Roland Morris Disability Questionnaire.
Study Details
Timeline
Interventions
Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months